BHVN Form 8-K: Q2 2025 Results Released via Press Release (Exhibit 99.1)

Rhea-AI Filing Summary

Biohaven Ltd. furnished a Current Report on Form 8-K to announce a press release reporting its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and the cover page of the report is provided in Inline XBRL as Exhibit 104.

The filing states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, and is not incorporated by reference in other filings except by specific reference. The registrant is organized in the British Virgin Islands, its common shares trade under BHVN on the New York Stock Exchange, and the report is signed by Chief Financial Officer Matthew Buten.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure; 8-K furnishes a press release with Q2 results but contains no financial figures itself.

The Form 8-K furnishes rather than files a press release announcing results for the quarter ended June 30, 2025, and attaches Exhibit 99.1 plus an Inline XBRL cover page as Exhibit 104. Because the body of the 8-K contains no revenue, earnings, or guidance figures, the filing itself does not add quantitative information for valuation or modeling. Investors must review the press release exhibit for material metrics; absent those figures, this filing is neutral in impact.

Corporate Governance Expert

TL;DR: Procedural disclosure confirming a press release and limiting Section 18 liability; follows standard governance practice.

The registrant explicitly states the furnished material is not "filed" under Section 18, which limits the 8-K text's incorporation and related liability. The inclusion of Exhibit 99.1 and the Inline XBRL cover page, plus a signature by the CFO, align with routine SEC disclosure procedures. There are no governance actions, officer changes, or material transactions disclosed in this report.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001935979false00019359792025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Biohaven Ltd.

(Exact name of registrant as specified in its charter)

British Virgin Islands			001-41477			Not applicable
(State or other jurisdiction of incorporation)			(Commission File Number)			(IRS Employer Identification No.)

c/o Biohaven Pharmaceuticals, Inc.

215 Church Street

New Haven, Connecticut 06510

(Address of principal executive offices, including zip code)

(203) 404-0410

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading symbol			Name of each exchange on which registered
Common Shares, no par value			BHVN			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 2.02    Results of Operations and Financial Condition.

On August 11, 2025, Biohaven Ltd. (the “Registrant”) issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

Item 9.01    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Exhibit Description
99.1						Press Release, dated August 11, 2025, "Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments."
104						The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 11, 2025

Biohaven Ltd.
By:			/s/ Matthew Buten
			Matthew Buten
			Chief Financial Officer

3

FAQ

What does the Biohaven (BHVN) 8-K disclose?

The 8-K furnishes a press release announcing Biohaven's financial results for the second quarter ended June 30, 2025, attached as Exhibit 99.1, and includes an Inline XBRL cover page as Exhibit 104.

Is the information in the 8-K considered "filed" under the Exchange Act?

No. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Does the 8-K itself include financial figures for Q2 2025?

No. The 8-K text notifies of a press release with results but does not include specific financial metrics; those would be in Exhibit 99.1.

Where is Biohaven incorporated and where do its shares trade?

Biohaven Ltd. is organized in the British Virgin Islands and its common shares trade under the ticker BHVN on the New York Stock Exchange.

Who signed the 8-K for Biohaven?

The report is signed on behalf of Biohaven by Matthew Buten, Chief Financial Officer.